S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
All the trading advice you’ve ever received boils down to this (Ad)
How does the Consumer Price Index affect the stock market?
3 biotech powerhouses poised to thrive amid sector rebound
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Broadcom falls into a buy-the-dip opportunity 
A 'soft landing' or a recession? How each one might affect America's households and businesses
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
All the trading advice you’ve ever received boils down to this (Ad)
How does the Consumer Price Index affect the stock market?
3 biotech powerhouses poised to thrive amid sector rebound
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Broadcom falls into a buy-the-dip opportunity 
A 'soft landing' or a recession? How each one might affect America's households and businesses
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
All the trading advice you’ve ever received boils down to this (Ad)
How does the Consumer Price Index affect the stock market?
3 biotech powerhouses poised to thrive amid sector rebound
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Broadcom falls into a buy-the-dip opportunity 
A 'soft landing' or a recession? How each one might affect America's households and businesses
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
All the trading advice you’ve ever received boils down to this (Ad)
How does the Consumer Price Index affect the stock market?
3 biotech powerhouses poised to thrive amid sector rebound
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Broadcom falls into a buy-the-dip opportunity 
A 'soft landing' or a recession? How each one might affect America's households and businesses
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023

Jasper Therapeutics Stock Price, News & Analysis (NASDAQ:JSPR)

$0.51
-0.01 (-1.92%)
(As of 12/8/2023 ET)
Compare
Today's Range
$0.48
$0.53
50-Day Range
$0.51
$0.93
52-Week Range
$0.39
$3.80
Volume
2.01 million shs
Average Volume
272,043 shs
Market Capitalization
$56.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.96

Jasper Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,069.1% Upside
$5.96 Price Target
Short Interest
Bearish
2.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$12,300 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.62) to ($0.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

349th out of 942 stocks

Biological Products, Except Diagnostic Industry

57th out of 161 stocks


JSPR stock logo

About Jasper Therapeutics Stock (NASDAQ:JSPR)

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

JSPR Stock Price History

JSPR Stock News Headlines

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Jasper Therapeutics: Q3 Earnings Insights
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Jasper Therapeutics Inc.
Jasper Therapeutics Appoints Herb Cross As New CFO
Jasper Therapeutics (NASDAQ: JSPR)
See More Headlines
Receive JSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/13/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JSPR
Fax
N/A
Employees
35
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.96
High Stock Price Target
$7.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+1,069.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-37,690,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.95 per share

Miscellaneous

Free Float
107,224,000
Market Cap
$56.90 million
Optionable
Not Optionable
Beta
1.91
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Ronald A. Martell (Age 61)
    President, CEO & Director
    Comp: $892.45k
  • Dr. Judith Anne Shizuru M.D. (Age 67)
    Ph.D., Co-Founder, Chair of Scientific Advisory Board & Director
    Comp: $291.25k
  • Mr. Jeetinder Singh Mahal M.B.A. (Age 51)
    Chief Operating Officer
    Comp: $579.46k
  • Mr. Herbert C. Cross (Age 51)
    CFO & Corporate Secretary
  • Dr. Luca Di Noto Ph.D.
    Senior Vice President of Technical Operations
  • Mr. David Ku M.D.
    Vice President of Corporate Development, Portfolio Strategy & Management
  • Mr. Matthew Ford
    Vice President of Human Resources
  • Dr. Wendy Pang M.D.
    Ph.D., Senior Vice President of Research & Translational Medicine
  • Dr. Edwin Jonathan Tucker M.D. (Age 51)
    Chief Medical Officer
  • Ms. Patricia Carlos
    Senior Vice President of Regulatory Affairs & Quality














JSPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Jasper Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JSPR shares.
View JSPR analyst ratings
or view top-rated stocks.

What is Jasper Therapeutics' stock price target for 2024?

5 Wall Street research analysts have issued 1 year price targets for Jasper Therapeutics' stock. Their JSPR share price targets range from $4.00 to $7.00. On average, they predict the company's stock price to reach $5.96 in the next twelve months. This suggests a possible upside of 1,069.1% from the stock's current price.
View analysts price targets for JSPR
or view top-rated stocks among Wall Street analysts.

How have JSPR shares performed in 2023?

Jasper Therapeutics' stock was trading at $0.4829 on January 1st, 2023. Since then, JSPR stock has increased by 5.6% and is now trading at $0.51.
View the best growth stocks for 2023 here
.

When is Jasper Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024.
View our JSPR earnings forecast
.

How were Jasper Therapeutics' earnings last quarter?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.01.

Who are Jasper Therapeutics' major shareholders?

Jasper Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Mariner LLC (0.59%), Cowen AND Company LLC (0.18%), Forefront Analytics LLC (0.10%), Summit Trail Advisors LLC (0.06%) and Walleye Capital LLC (0.00%). Insiders that own company stock include Anna Louise French, Carlyle Group Inc, Holding Ltd Roche, Jeetinder Singh Mahal, Thomas G Wiggans and William Lis.
View institutional ownership trends
.

How do I buy shares of Jasper Therapeutics?

Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:JSPR) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -